120 related articles for article (PubMed ID: 31720670)
1. Adenine-(methoxy)-ethoxy-P
Nassir M; Mirza S; Arad U; Lee S; Rafehi M; Yaw Attah I; Renn C; Zimmermann H; Pelletier J; Sévigny J; Müller CE; Fischer B
Org Biomol Chem; 2019 Nov; 17(46):9913-9923. PubMed ID: 31720670
[TBL] [Abstract][Full Text] [Related]
2. Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes.
Nassir M; Arad U; Lee SY; Journo S; Mirza S; Renn C; Zimmermann H; Pelletier J; Sévigny J; Müller CE; Fischer B
Purinergic Signal; 2019 Jun; 15(2):247-263. PubMed ID: 31025169
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship study of NPP1 inhibitors based on uracil-N1-(methoxy)ethyl-β-phosphate scaffold.
Nassir M; Pelletier J; Arad U; Arguin G; Khazanov N; Gendron FP; Sévigny J; Senderowitz H; Fischer B
Eur J Med Chem; 2019 Dec; 184():111754. PubMed ID: 31610377
[TBL] [Abstract][Full Text] [Related]
4. Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
Zelikman V; Pelletier J; Simhaev L; Sela A; Gendron FP; Arguin G; Senderowitz H; Sévigny J; Fischer B
J Med Chem; 2018 May; 61(9):3939-3951. PubMed ID: 29681152
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug.
Danino O; Svetitsky S; Kenigsberg S; Levin A; Journo S; Gold A; Drexler M; Snir N; Elkayam O; Fischer B; Arad U
Rheumatology (Oxford); 2018 Aug; 57(8):1472-1480. PubMed ID: 29688536
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase/phosphodiesterase inhibitors and antiproliferative agents.
Ullah S; El-Gamal MI; El-Gamal R; Pelletier J; Sévigny J; Shehata MK; Anbar HS; Iqbal J
Eur J Med Chem; 2021 May; 217():113339. PubMed ID: 33744686
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of sulfonate and sulfamate derivatives possessing benzofuran or benzothiophene nucleus as inhibitors of nucleotide pyrophosphatases/phosphodiesterases and anticancer agents.
Anbar HS; El-Gamal R; Ullah S; Zaraei SO; Al-Rashida M; Zaib S; Pelletier J; Sévigny J; Iqbal J; El-Gamal MI
Bioorg Chem; 2020 Nov; 104():104305. PubMed ID: 33017718
[TBL] [Abstract][Full Text] [Related]
8. Nonhydrolyzable ATP analogues as selective inhibitors of human NPP1: a combined computational/experimental study.
Lecka J; Ben-David G; Simhaev L; Eliahu S; Oscar J; Luyindula P; Pelletier J; Fischer B; Senderowitz H; Sévigny J
J Med Chem; 2013 Nov; 56(21):8308-20. PubMed ID: 24083941
[TBL] [Abstract][Full Text] [Related]
9. Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases.
Vollmayer P; Clair T; Goding JW; Sano K; Servos J; Zimmermann H
Eur J Biochem; 2003 Jul; 270(14):2971-8. PubMed ID: 12846830
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1.
Forcellini E; Boutin S; Lefebvre CA; Shayhidin EE; Boulanger MC; Rhéaume G; Barbeau X; Lagüe P; Mathieu P; Paquin JF
Eur J Med Chem; 2018 Mar; 147():130-149. PubMed ID: 29427906
[TBL] [Abstract][Full Text] [Related]
11. Large-volume sample stacking with polarity switching for monitoring of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) reactions by capillary electrophoresis.
Lee SY; Müller CE
Electrophoresis; 2014 Mar; 35(6):855-63. PubMed ID: 24431193
[TBL] [Abstract][Full Text] [Related]
12. Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.
Nadel Y; Lecka J; Gilad Y; Ben-David G; Förster D; Reiser G; Kenigsberg S; Camden J; Weisman GA; Senderowitz H; Sévigny J; Fischer B
J Med Chem; 2014 Jun; 57(11):4677-91. PubMed ID: 24846781
[TBL] [Abstract][Full Text] [Related]
13. Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice.
Bertrand J; Nitschke Y; Fuerst M; Hermann S; Schäfers M; Sherwood J; Nalesso G; Ruether W; Rutsch F; Dell'Accio F; Pap T
Ann Rheum Dis; 2012 Jul; 71(7):1249-53. PubMed ID: 22510396
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and computational studies of highly selective inhibitors of human recombinant tissue non-specific alkaline phosphatase (h-TNAP): A therapeutic target against vascular calcification.
Andleeb H; Hussain M; Abida Ejaz S; Sevigny J; Farman M; Yasinzai M; Zhang J; Iqbal J; Hameed S
Bioorg Chem; 2020 Aug; 101():103999. PubMed ID: 32563966
[TBL] [Abstract][Full Text] [Related]
15. Modulation of chondrocyte production of extracellular inorganic pyrophosphate.
Costello JC; Ryan LM
Curr Opin Rheumatol; 2004 May; 16(3):268-72. PubMed ID: 15103256
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and docking studies of new raloxifene sulfonate or sulfamate derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase.
El-Gamal MI; Ullah S; Zaraei SO; Jalil S; Zaib S; Zaher DM; Omar HA; Anbar HS; Pelletier J; Sévigny J; Iqbal J
Eur J Med Chem; 2019 Nov; 181():111560. PubMed ID: 31382118
[TBL] [Abstract][Full Text] [Related]
17. Probing the high potency of pyrazolyl pyrimidinetriones and thioxopyrimidinediones as selective and efficient non-nucleotide inhibitors of recombinant human ectonucleotidases.
Andleeb H; Hameed S; Ejaz SA; Khan I; Zaib S; Lecka J; Sévigny J; Iqbal J
Bioorg Chem; 2019 Jul; 88():102893. PubMed ID: 30986550
[TBL] [Abstract][Full Text] [Related]
18. Thiazolo[3,2-a]benzimidazol-3(2H)-one derivatives: Structure-activity relationships of selective nucleotide pyrophosphatase/phosphodiesterase1 (NPP1) inhibitors.
Lee SY; Perotti A; De Jonghe S; Herdewijn P; Hanck T; Müller CE
Bioorg Med Chem; 2016 Jul; 24(14):3157-65. PubMed ID: 27265686
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormones induce features of the hypertrophic phenotype and stimulate correlates of CPPD crystal formation in articular chondrocytes.
Rosenthal AK; Henry LA
J Rheumatol; 1999 Feb; 26(2):395-401. PubMed ID: 9972975
[TBL] [Abstract][Full Text] [Related]
20. Ankylosing spondylitis, late osteoarthritis, vascular calcification, chondrocalcinosis and pseudo gout: toward a possible drug therapy.
Mebarek S; Hamade E; Thouverey C; Bandorowicz-Pikula J; Pikula S; Magne D; Buchet R
Curr Med Chem; 2011; 18(14):2196-203. PubMed ID: 21517761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
